Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment

Authors not listed

Hadassah Medical Organization · 2024

Abstract

The goal of this clinical trial is to learn if the drug Egb761, produced from Ginkgo Biloba extract, works to improve the blood level of a biomarker of Alzheimer's disease, called phosphorylated-tau217 (p-tau217), which serves as a biomarker for disease activity in the brain. The main questions it aims to answer are: Does drug Egb761 lower the plasma level of p-tau217 in patients with mild cognitive impairment? Does drug Egb761 improve cognitive and behavioral functions in these patients? Does Egb761 affect the blood levels of neurofilament-light (Nfl) and glial-fibrillary-acidic-protein (GFAP), which serve as additional biomarkers for brain disease activity? Participants will: Take Egb761 twice daily for 6 months Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
Anonymous. (2024). Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment. <em>Hadassah Medical Organization</em>. https://clinicaltrials.gov/study/NCT07287852
Vancouver
Anonymous. Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment. Hadassah Medical Organization. 2024.
BibTeX
@misc{anon2024IsCere, title = {Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment}, author = {Anonymous}, journal = {Hadassah Medical Organization}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings